Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...

During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...

Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...

Months ahead of the target action date, the FDA recently approved the pan-RAS inhibitor daraxonrasib (Rasonque) for patients ...

The FDA has granted fast track designation (FTD) to ERAS-0015, an oral pan-RAS molecular glue, clearing an expedited ...

The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.

In the GESTALT feasibility and safety trial, GammaTile reduced rapid early progression to 6% vs a historical 50% to 80%, with ...

Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia. Immune ...

Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...

The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...

The first patient has been dosed in MODeFIRe-1 (NCT07745361), a phase 2 study evaluating MRT-2359 in combination with ...